Düsseldorf, Germany – November 26, 2025
mAIbe and LenioBio are pleased to announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies.
By combining mAIbe’s AI-driven platform for antibody design and optimization with LenioBio’s cell-free expression technology, this partnership brings together two complementary strengths to significantly enhance the design–build–test cycle.
LenioBio’s ultrafast, scalable expression system enables rapid production of complex antibodies, providing high-quality experimental data that feeds directly into mAIbe’s AI models.
Through this integrated approach, the two teams will jointly:
- accelerate functional testing of AI-generated antibody candidates
- increase the efficiency and throughput of early validation
- enable faster iteration between computational predictions and experimental results
Together, mAIbe and LenioBio set a new standard for speed, flexibility, and data-driven innovation in therapeutic antibody discovery by closing the lab-in-loop gap.
About LenioBio
LenioBio GmbH is a biotechnology company pioneering cell-free protein expression with its ALiCE® platform, enabling rapid discovery, development, and scalable production of proteins beyond the limits of living cells. Founded in Germany in 2016, LenioBio is headquartered in Düsseldorf with R&D and manufacturing facilities in Aachen.
Learn more at www.leniobio.com and follow us on LinkedIn.
About mAlbe
mAIbe is a biotechnology company focused on AI-guided monoclonal antibody design. Its platform combines physics-informed generative AI and synthetic biology to develop precise, cost-effective antibodies targeting viral and bacterial pathogens. Based in Rome, Italy, mAIbe operates at the convergence of artificial intelligence and life sciences to accelerate the development of accessible, next-generation immunotherapies.
Learn more at www.maibe.eu
Media Contact:
Akanksha Ranjit
Marketing & Communications
LenioBio GmbH
a.ranjit@leniobio.com